Zobrazeno 1 - 3
of 3
pro vyhledávání: ''
Autor:
Anca Boldea, Stefanie Schier-Mumzhiu, Anne Bellon, Ahad Sabet, Sven D. Koch, Celine Schelcher, Maria Velinova, Roumen Nakov, Sreekanth Gattu, Daniel Dickerson, Andrej Skerjanec, Charles Tomek, Steven Schussler, Jessie Wang, Terry O'Reilly, Ly Ngo, Gordon P. Otto, Miryana Dobreva
Publikováno v:
British Journal of Clinical Pharmacology
Aims Recombinant PEGylated human granulocyte colony-stimulating factor (pegfilgrastim) is indicated for the reduction of chemotherapy-induced neutropenia and prevention of febrile neutropenia. Biosimilar pegfilgrastim is expected to reduce the financ
Autor:
Valentina Mongelli, Annalisa Piccinno, Massimo Corradi, Frans van den Berg, Dave Singh, Brian Leaker, Brian J. Lipworth, Sara Collarini, Sunny Jabbal, Sonia Biondaro, Luigi Santoro
Publikováno v:
British Journal of Clinical Pharmacology
Singh, D, van den Berg, F, Leaker, B, Corradi, M, Jabbal, S, Collarini, S, Mongelli, V, Santoro, L, Piccinno, A, Biondaro, S & Lipworth, B 2019, ' Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction : A noninferiority study using metered dose vs. dry powder inhaler ', British Journal of Clinical Pharmacology . https://doi.org/10.1111/bcp.13847
Singh, D, van den Berg, F, Leaker, B, Corradi, M, Jabbal, S, Collarini, S, Mongelli, V, Santoro, L, Piccinno, A, Biondaro, S & Lipworth, B 2019, ' Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction : A noninferiority study using metered dose vs. dry powder inhaler ', British Journal of Clinical Pharmacology . https://doi.org/10.1111/bcp.13847
Aims: To demonstrate the noninferiority of extrafine beclomethasone/formoterol fumarate (BDP/FF) dry powder inhaler (DPI) vs. extrafine BDP/FF pressurized metered dose inhaler (pMDI; Foster® 100/6 μg NEXThaler and pMDI, respectively) in the onset o
Autor:
Ming Dauh Wang, Stephen J. Nicholls, Ellen A. Cannady, Stuart Friedrich, Jessica Rehmel, Jeffrey G. Suico, Kathryn A. Krueger
Publikováno v:
British Journal of Clinical Pharmacology
Aims Evacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor under development for reducing cardiovascular events in patients with high risk vascular disease. CETP inhibitors are likely to be utilized as ‘add-on’ therapy to statins i